Can you take Metyrosine with Suvorexant?

Suvorexant has a major potential interaction with Depression.

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics. Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations. These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation. Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

Suvorexant has a moderate potential interaction with Glaucoma/Intraocular Hypertension.

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.

Suvorexant has a moderate potential interaction with Liver Disease.

In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly. Laboratory testing is recommended prior and during treatment.

Suvorexant has a major potential interaction with Narcolepsy.

The use of suvorexant is contraindicated in patient with narcolepsy.

metyroSINE has a moderate potential interaction with Parkinsonism.

Extrapyramidal symptoms (EPS) have occurred in approximately 10% of patients receiving metyrosine. EPS include drooling, speech difficulty, and tremor. Trismus and parkinsonian syndrome have been reported. Therapy with metyrosine should be administered cautiously in patients with or predisposition to EPS or Parkinson's disease. Dosage reduction or discontinuation of metyrosine may be necessary.

metyroSINE has a moderate potential interaction with Psychosis.

Anxiety, excitability, and psychic disturbances such as hallucinations, disorientation/confusion, emotional instability, and depression have occurred in patients receiving metyrosine. Therapy with metyrosine should be administered cautiously in patients with psychiatric and/or emotional disorders. Dosage reduction may be appropriate. Clinical monitoring of emotional and psychiatric status is recommended.

Suvorexant has a major potential interaction with Pulmonary Impairment.

Suvorexant has respiratory depressant effects and should be used with caution in patients with compromised respiratory function. Suvorexant has not been studied in patients with severe sleep apnea and severe COPD and should not be used in these patients.

Suvorexant has a major potential interaction with Renal Dysfunction.

Some anxiolytic, sedative and hypnotic drugs have not been studied in patients with severe renal impairment and should not be used on these patients.

metyroSINE has a moderate potential interaction with Renal Dysfunction.

Metyrosine is primarily eliminated by the kidney. The serum concentration of metyrosine may be increased in patients with renal impairment. Therapy with metyrosine should be administered cautiously in patient with compromised renal function. Clinical monitoring of renal function is recommended.

Suvorexant has a moderate potential interaction with Urinary Retention.

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.